SCHEMBL23607906

SCHEMBL23607906

O=C(O)NCCN(Cc1ccc(F)cc1)C(=O)c1ccc(Br)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 6/20 0.44
HDAC6 Q9UBN7 6/20 0.44
ROCK1 Q13464 1/20 0.43
NR1H4 Q96RI1 1/20 0.43
HDAC3 O15379 1/20 0.43
HDAC7 Q8WUI4 1/20 0.43
HDAC10 Q969S8 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
MCHR1 Q99705 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
TMEM97 Q5BJF2 2/20 0.42
SIGMAR1 Q99720 2/20 0.42
ACKR3 P25106 1/20 0.42
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
ALDH1A1 P00352 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
OPRK1 P41145 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23616006 0.83 MAPT (0.41) HDAC1HDAC6ROCK1NR1H4HDAC3
SCHEMBL28595864 0.76 ROCK1 (0.47) HDAC1HDAC6ROCK1MCHR1NPC1
SCHEMBL5300837 0.73 ACKR3 (0.42) HDAC1HDAC6ROCK1HDAC3MCHR1
SCHEMBL5121399 0.73 TRPM8 (0.54) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL20742852 0.72 BCL2L1 (0.40) ROCK1MCHR1NPC1RAB9ALMNA
SCHEMBL5332700 0.71 TSHR (0.56) L3MBTL1MEN1KMT2ATMEM97SIGMAR1
SCHEMBL250873 0.70 PLAAT3 (0.58) KMT2ANPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL30941107 0.70 NPC1 (0.62) MEN1KMT2ANPC1RAB9AALDH1A1
SCHEMBL2415459 0.70 STAT3 (0.51) ROCK1MCHR1MEN1KMT2AALDH1A1
SCHEMBL11884007 0.70 REN (0.57) HDAC1HDAC6HDAC3HDAC7HDAC10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113121443-B Beta-amino acid derivatives, kinase inhibitors and pharmaceutical compositions containing them and their use 财团法人工业技术研究院 2024-07-09 CN disclosed
US-11608319-B2 Beta-amino acid derivative, kinase inhibitor and pharmaceutical composition containing the same, and method for performing an in vivo related application that benefits from the inhibition of a kinase INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) 2023-03-21 US disclosed
EP-3845276-A1 SS-AMINO ACID DERIVATIVE, KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, AND USE OF THE SAME Industrial Technology Research Institute (TW) 2021-07-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11608319-B2 Beta-amino acid derivative, kinase inhibitor and pharmaceutical composition containing the same, and method for performing an in vivo related application that benefits from the inhibition of a kinase CSNK1A1, CSNK1D, CSNK1G3 HDAC1 981/4885HDAC6 1952/4885ROCK1 716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.